MaxCyte (MXCT) Stock Price
MaxCyte Price
Over the last 12 years MaxCyte grew revenue by 18.5% annually, reaching 38.63 M USD. For MaxCyte, the net margin of -106.3% is down versus -45.2% a few years ago. The consensus 12-month price target for MaxCyte is 5.83 USD, about 359.4% above where the stock trades today. Of 13 analysts, 10 rate the stock a buy — an overall Buy consensus. The stock trades about 88% above its 52-week low.
MaxCyte stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of MaxCyte over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how MaxCyte stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing MaxCyte's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | MaxCyte Price |
|---|---|
| 9/2/2026 | 1.27 USD |
| 9/1/2026 | 1.24 USD |
| 8/31/2026 | 1.29 USD |
| 8/28/2026 | 1.23 USD |
| 8/27/2026 | 1.31 USD |
| 8/26/2026 | 1.31 USD |
| 8/25/2026 | 1.35 USD |
| 8/24/2026 | 1.39 USD |
| 8/21/2026 | 1.38 USD |
| 8/20/2026 | 1.38 USD |
| 8/19/2026 | 1.37 USD |
| 8/18/2026 | 1.29 USD |
| 8/17/2026 | 1.32 USD |
| 8/14/2026 | 1.32 USD |
| 8/13/2026 | 1.39 USD |
| 8/12/2026 | 1.25 USD |
| 8/10/2026 | 1.21 USD |
| 8/7/2026 | 1.18 USD |
| 8/6/2026 | 1.11 USD |
| 8/5/2026 | 1.10 USD |
| 8/4/2026 | 1.11 USD |
| 8/3/2026 | 1.07 USD |
| 7/31/2026 | 1.05 USD |
| 7/30/2026 | 1.05 USD |
| 7/29/2026 | 1.01 USD |
| 7/28/2026 | 1.05 USD |
| 7/27/2026 | 1.02 USD |
| 7/24/2026 | 1.08 USD |
| 7/23/2026 | 1.12 USD |
| 7/22/2026 | 1.14 USD |
MaxCyte Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
MaxCyte Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.00 | 13.00 | 16.00 | 21.00 | 26.00 | 33.00 | 44.00 | 41.00 | 38.00 | 35.00 | 31.00 | 37.00 | 44.00 | 81.00 | 146.00 | 219.00 |
| 33.33 | 8.33 | 23.08 | 31.25 | 23.81 | 26.92 | 33.33 | -6.82 | -7.32 | -7.89 | -11.43 | 19.35 | 18.92 | 84.09 | 80.25 | 50.00 |
| 83.33 | 92.31 | 87.50 | 90.48 | 88.46 | 90.91 | 88.64 | 87.80 | 81.58 | 81.58 | 81.58 | 81.58 | 81.58 | 81.58 | 81.58 | 81.58 |
| 10.00 | 12.00 | 14.00 | 19.00 | 23.00 | 30.00 | 39.00 | 36.00 | 31.00 | 28.55 | 25.29 | 30.18 | 35.89 | 66.08 | 119.11 | 178.66 |
| -2.00 | -9.00 | -8.00 | -12.00 | -11.00 | -18.00 | -27.00 | -48.00 | -51.00 | -27.00 | -25.00 | -29.00 | -35.00 | -64.00 | 29.00 | – |
| -16.67 | -69.23 | -50.00 | -57.14 | -42.31 | -54.55 | -61.36 | -117.07 | -134.21 | -77.14 | -80.65 | -78.38 | -79.55 | -79.01 | 19.86 | – |
| -3.00 | -9.00 | -8.00 | -12.00 | -11.00 | -19.00 | -23.00 | -37.00 | -41.00 | -41.00 | -30.00 | -28.00 | -21.00 | -11.00 | – | – |
| – | 200.00 | -11.11 | 50.00 | -8.33 | 72.73 | 21.05 | 60.87 | 10.81 | – | -26.83 | -6.67 | -25.00 | -47.62 | – | – |
| 33.52 | 48.64 | 51.18 | 56.40 | 69.46 | 90.62 | 101.70 | 103.27 | 104.85 | 104.85 | 104.85 | 104.85 | 104.85 | 104.85 | 104.85 | 104.85 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales MaxCyte generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue MaxCyte retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare MaxCyte's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares MaxCyte has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against MaxCyte's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
MaxCyte stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
MaxCyte Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
MaxCyte business model & stock analysis
MaxCyte SWOT Analysis
Strengths
MaxCyte Inc has a strong reputation in the biotechnology industry, known for its innovative cell transfection technology.
The company has a solid intellectual property portfolio, protecting its technology and giving it a competitive edge.
MaxCyte Inc has established strategic partnerships with leading pharmaceutical companies, allowing for collaborative research and development opportunities.
With a skilled and experienced workforce, MaxCyte Inc possesses the necessary expertise to drive its growth and success.
Weaknesses
MaxCyte Inc's operations heavily rely on a few key clients, creating a potential risk of loss if these clients reduce their business or terminate contracts.
The company may face challenges in penetrating new markets due to intense competition and regulatory hurdles in the biotechnology industry.
MaxCyte Inc's financial performance is not as strong as some of its competitors, potentially limiting its ability to invest in research and development.
Opportunities
The growing demand for cell-based therapies presents an excellent opportunity for MaxCyte Inc to expand its market presence and increase revenues.
The company can leverage its technology to target the gene editing market, which is experiencing significant growth and offers promising commercial potential.
MaxCyte Inc can explore partnerships with academic institutions and research organizations to tap into emerging scientific advancements and broaden its product offerings.
Threats
MaxCyte Inc faces the risk of new entrants in the cell transfection technology market, which may challenge its market share and competitive position.
Changes in government regulations or policies related to biotechnology and gene editing could impact the company's operations and hinder its growth prospects.
The global economic conditions and fluctuations in exchange rates pose a threat to MaxCyte Inc's international operations and revenue streams.
MaxCyte Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
MaxCyte historical P/E ratio, EBIT multiple, and P/S ratio
MaxCyte annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
MaxCyte shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current MaxCyte forecasts and price targets in September 2026
Analyst Price Targets 2026MaxCyte Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/12/2026 | -0.10USD | - | 6.60 MUSD | - | 2026 Q2 |
| 5/13/2026 | -0.08USD | - | 7.44 MUSD | - | 2026 Q1 |
| 3/24/2026 | -0.08USD | - | 9.59 MUSD | - | 2025 Q4 |
| 3/16/2024 | -0.11USD | - | 9.60 MUSD | - | 2023 Q4 |
| 11/9/2022 | -0.09USD | - | 10.59 MUSD | - | 2022 Q3 |
| 8/10/2022 | -0.08USD | - | 9.36 MUSD | - | 2022 Q2 |
| 5/9/2022 | -0.07USD | - | 8.59 MUSD | - | 2022 Q1 |
| 3/22/2022 | -0.06USD | - | 9.60 MUSD | - | 2021 Q4 |
| 11/10/2021 | -0.05USD | - | 7.48 MUSD | - | 2021 Q3 |
| 9/13/2021 | -0.07USD | - | 5.82 MUSD | - | 2021 Q2 |
EESG©
Eulerpool ESG Scorecard© for the MaxCyte stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
MaxCyte shareholder structure
| % | Name |
|---|---|
5.15370% | |
2.06466% | |
1.26559% | |
0.65623% | |
0.37342% | |
0.21616% |
MaxCyte Executives and Management Board
11 members · avg. age 61 · 18 % women
Mr. Maher Masoud (50)
President, Chief Executive Officer, Director · since 2020
3.61 M USD
Management
Mr. Douglas Swirsky (55)
Chief Financial Officer
Mr. David Sandoval (47)
Senior Vice President, General Counsel, Corporate Secretary
Board of Directors
Ms. Cynthia Collins (67)
Non-Executive Independent Director
Dr. Richard Douglas (72)
Non-Executive Independent Chairman of the Board
Mr. William Brooke (69)
Non-Executive Independent Director
Ms. Rekha Hemrajani (55)
Non-Executive Independent Director
Mr. Stanley Erck (77)
Non-Executive Independent Director
Mr. Patrick Balthrop (68)
Non-Executive Independent Director
Frequently asked questions about MaxCyte
The main competitors of MaxCyte Inc in the market include companies such as Thermo Fisher Scientific, Lonza Group, and Mirus Bio LLC. Thermo Fisher Scientific, a leading life sciences company, offers a range of products and services that overlap with MaxCyte Inc's transfection technology. Lonza Group, a multinational company, also provides cell and gene therapy solutions that compete with MaxCyte Inc's offerings. Mirus Bio LLC, a biotechnology company, focuses on developing innovative transfection reagents, making them a direct competitor in this space.
MaxCyte Inc is a renowned biotechnology company specializing in cell engineering and drug discovery. Founded in 1999, MaxCyte has established a strong presence in the life sciences industry. The company's innovative cell engineering platform, known as Flow Electroporation™ Technology, enables precise genetic modification of cells for various applications, including cell-based therapies, gene editing, and biomanufacturing. With a global customer base and strategic partnerships, MaxCyte continues to advance its technology and contribute to groundbreaking research in the field of biotechnology. MaxCyte Inc has emerged as a key player in shaping the future of personalized medicine and regenerative therapies.
MaxCyte Inc is a biotechnology company specializing in cell-based therapies and life sciences. Their business model revolves around providing innovative solutions for cell engineering and drug development. MaxCyte's proprietary technology enables the efficient delivery of molecules into cells, ensuring targeted genetic modification and enhanced therapeutic efficacy. With a focus on collaborations and licensing agreements, MaxCyte aims to expand its reach across various therapeutic areas, including cancer, vaccines, gene editing, and regenerative medicine. By leveraging their expertise in high-performance cell engineering, MaxCyte Inc strives to revolutionize the field of medicine and contribute to the development of novel treatments.
MaxCyte Inc is primarily active in the biotechnology industry.
MaxCyte Inc has achieved significant milestones in its journey. The company has made remarkable advancements in the field of cell engineering and cutting-edge cell-based therapies. MaxCyte's proprietary technology, Flow Electroporation™, has revolutionized the delivery of nucleic acids, proteins, and cell-based therapeutics. The company has successfully developed a broad range of partnerships and collaborations with renowned pharmaceutical and biotechnology companies worldwide. MaxCyte has also received numerous grants and awards recognizing its contributions to the field. Through continuous innovation and strategic collaborations, MaxCyte Inc continues to strengthen its position as a leading player in the biotechnology industry.
MaxCyte Inc is primarily present in the United States, as it is a Maryland-based biotechnology company. However, the company also has a global presence, with operations and collaborations in various countries and regions worldwide. Some notable regions where MaxCyte Inc has a presence include Europe, Asia-Pacific, and the Middle East. With its versatile cell engineering platform, MaxCyte Inc continues to expand its reach and partnerships internationally, catering to the demands of the biotech industry globally while focusing on its headquarters in the United States.
MaxCyte Inc represents a strong commitment to innovation and scientific excellence. The company values include providing cutting-edge cell engineering solutions and transformative technology for the advancement of healthcare and biotechnology. MaxCyte Inc's corporate philosophy focuses on delivering high-quality products and services, fostering collaboration among researchers, and driving advancements in cell-based therapies and drug discovery. By prioritizing customer satisfaction and continuous improvement, MaxCyte Inc aims to contribute to the progress of life sciences industry.
Analysts currently set an average price target of 6.47 USD for the MaxCyte stock (median: 5.83 USD), implying +413.6 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the MaxCyte stock: 10 recommend buying, 3 holding and 0 selling. For 2026, analysts expect MaxCyte to generate revenue of 31.45 M USD and earnings per share of -0.29 USD.
Converted at the current exchange rate, the MaxCyte share trades at 1.09 EUR (1.27 USD).
The MaxCyte share (MXCT) is listed on 5 stock exchanges, including: NASDAQ (MXCT), Frankfurt (MYE0.F), München (MYE0.MU), London (MXCT.L), London (MXCT.L).
MaxCyte Inc is an emerging biotechnology company specializing in the development of platform technologies for the rapid and efficient production of therapeutics and vaccines. Its business model is based on selling licenses and providing services to companies in the biotech and pharma industries. The company offers a versatile technology platform for the production of high-quality products with higher throughput and shorter production times. MaxCyte has developed a proprietary technology called electroporation, which allows for the direct transfer of DNA, RNA, proteins, and other molecules into cells. The company offers customers the opportunity to utilize this technology through licensing agreements to manufacture their own products or develop new therapeutic candidates. MaxCyte is divided into two business segments: Services and Products. The Services segment offers a range of customized services, from product development to the manufacture of clinical compounds. The Products segment includes various products based on the electroporation-based technology platform. MaxCyte also has partnerships with several major pharmaceutical and biotechnology companies to integrate its technology platform into the development and production of new product candidates. Overall, MaxCyte's business model focuses on the development and marketing of effective and efficient platform technologies for the production of therapeutics and vaccines. The company has established a strong network that includes both biotech and pharmaceutical companies. As the demand for state-of-the-art production technologies continues to grow, MaxCyte will play an important role in this field. Answer: MaxCyte Inc is a biotechnology company specializing in the development of platform technologies for the production of therapeutics and vaccines. Its business model is based on selling licenses and providing services to biotech and pharma companies. MaxCyte has a proprietary electroporation technology for transferring molecules into cells. They offer customized services and products based on this technology. The company also has partnerships with major pharma and biotech firms. Overall, MaxCyte aims to develop and market efficient production technologies for therapeutics and vaccines.
The expected revenue of MaxCyte is 31.45 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of MaxCyte is -30.05 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of MaxCyte is currently -4.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the MaxCyte stock.
The price-to-sales ratio (P/S) of MaxCyte is currently 4.23. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the MaxCyte stock.
The Eulerpool Quality Score for MaxCyte is 3/10.
The ISIN of MaxCyte is US57777K1060. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of MaxCyte is A2AGVE. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of MaxCyte is MXCT. The ticker symbol is used to trade MaxCyte shares on the stock exchange.
MaxCyte paid dividends every year for the past 0 years.
MaxCyte is assigned to the 'Health' sector.
The dividends of MaxCyte are distributed in USD.
MaxCyte stock
MaxCyte Peer Group
MaxCyte Ticker
MaxCyte FIGI
All fundamentals and in-depth analysis of MaxCyte
Our stock analysis for MaxCyte stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MaxCyte. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.